Evaluation of a Prescription Strength 4% Hydroquinone/10% L-Ascorbic Acid Treatment System for Normal to Oily Skin

December 2011 | Volume 10 | Issue 12 | Original Article | 1455 | Copyright © December 2011

Suzanne Bruce MDa and JoAnne Watson DPMb

aSuzanne Bruce and Associates, PA, Houston, TX bOMP, Inc., Long Beach, CA

chemical sunscreen)-which aim to prevent the development of further photodamage by minimizing the exposure of the skin to UV light.
The tolerability of the system was generally good. Only mild adverse events were reported, the most common of which was facial skin dryness (occurring in 32% of patients). However, it is possible that dryness would occur less frequently in clinical practice when, free from the constraints of the clinical trial protocol, patients would be able to use a moisturizer as needed.


The investigator evaluations show that the system offers reductions in fine lines and wrinkles, tactile roughness, intensity of pigmentation, and laxity together with an increase in the lightness/ brightness of the skin. In addition, the patients considered that the system was easy to apply and resulted in smoother skin, softer skin, more even color tone, more radiant skin, a visible reduction in fine lines and wrinkles, and an improvement in the overall appearance of their skin.
Overall, the results of this study demonstrate that the prescription strength hydroquinone/L-ascorbic acid treatment system can be valuable as an early intervention strategy against photodamage in individuals with minimal or mild photodamage and hyperpigmentation. It is also suitable for patients who are not ready for retinoid therapy or more aggressive anti-aging regimens.


Dr. Bruce has received grants as an investigator for Actavis, Inc., Allergan, Inc., Cipher Pharmaceuticals, Inc., Contura International A/S, Dow Pharmaceutical Sciences, Inc., Fibrocell Science, Inc., Galderma R & D, Inc., Graceway Pharmaceuticals, LLC, Incyte Corporation, Intendis, Inc., Isolagen Technologies, Inc., Novartis Pharmaceutical Corporation, Nycomed US, Inc., Obagi Medical Products, Inc., Paddock Laboratories, Inc., Peplin, Inc., Perrigo Company, Revance Therapeutics, Inc., Schering-Plough Corporation, Solta Medical, Inc., Spear Pharmaceuticals, Inc., Stiefel Laboratories, Inc., Teva Pharmaceuticals, Inc., Tolmar, Inc., and Warner Chilcott Ltd. She has also received honoraria as a consultant for Allergan, Inc., Merz Aesthetics, Inc., Obagi Medical Products, Inc., SkinMedica, Inc., Solta Medical, Inc., and TRIA Beauty, Inc. Dr. Watson is an employee of, and holds stock and stock options in, OMP, Inc.


  1. Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg.  2008;27:170-176.
  2. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett.  2004;9:1-3.
  3. Farris PK. Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions. Dermatol Surg.  2005;31:814-817; discussion 818.
  4. Eberlein-KOnig B, Ring J. Relevance of vitamins C and E in cutaneous photoprotection. J Cosmet Dermatol.  2005;4:4-9.
  5. Keller KL, Fenske NA. Uses of vitamins A, C, and E and related compounds in dermatology: a review. J Am Acad Dermatol.  1998;39:611-625.
  6. Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol. 2003;48:1-19
  7. Tajima S, Pinnell SR. Ascorbic acid preferentially enhances type I and III collagen gene transcription in human skin fibroblasts. J Dermatol Sci.  1996;11:250-253.
  8. Burgess C. Topical vitamins. J Drugs Dermatol.  2008;7(suppl 7):s2-6.
  9. Pinnell SR, Yang H, Omar M. Topical L-ascorbic acid: percutaneous absorption studies. Dermatol Surg.  2001;27:137-142.
  10. Burke KE. Interaction of vitamins C and E as better cosmeceuticals. Dermatol Ther.  2007;20:314-321
  11. Agahigian H. Greater stability and absorption of bioavailable vitamin C in two optimized formulations compared with a leading competitor formulation. Poster 800 presented at the Summer Academy Meeting 2008 of the American Academy of Dermatology, July 30-August 3, 2008, Chicago, IL. http://www.aad.org/ElectronicPosters/Posters/ 800/800.pdf. Accessed January 6, 2011.
  12. Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol.  2003;48:866-874.
  13. Hughes-Formella BJ, Bohnsack K, Rippke F, et al. Anti-inflammatory effect of hamamelis lotion in a UVB erythema test. Dermatology.  1998;196:316-322.
  14. Feily A, Namazi MR. Aloe vera in dermatology: a brief review. G Ital Dermatol Venereol.  2009;144:85-91.
  15. Korting HC, Schafer-Korting M, Hart H, et al. Anti-inflammatory activity of hamamelis distillate applied topically to the skin. Influence of vehicle and dose. Eur J Clin Pharmacol.  1993;44:315-318.
  16. Masaki H, Sakaki S, Atsumi T, Sakurai H. Active-oxygen scavenging activity of plant extracts. Biol Pharm Bull.  1995;18:162-166.

Address for Correspondence

Suzanne Bruce MD1900 St. James PlaceSuite 600Houston, TX 77056Phone: (713) 796-9199Fax: (713) 627-1782sbruce@sba-skincare.com